ArticleTropical medicine and infectious disease2020
Funding for Chagas Disease: A 10-Year (2009-2018) Survey.
Article in Tropical medicine and infectious disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Association BetweenFrontiers in cardiovascular medicine · 2021Pooled it
- Financial toxicity and the economic burden of Chagas disease: a scoping review.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Evaluation of Quality of Care in Chagas Disease Cardiomyopathy.Global heart · 2026Article
- Inhibitory Activity of LDT10 and LDT119, New Saturated Cardanols, AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- A hybrid method for fusion cardiac biomarkers and echocardiography videos in the experimental classification of Trypanosoma cruzi infection.Biomedical engineering online · 2025Article
- Enantioselective Properties of Neglected Drug Nifurtimox on Polysaccharide and Macrocyclic Glycopeptide Chiral Stationary Phases by Green HPLC Separation Methods.Journal of separation science · 2025Article
- The patent landscape of Chagas disease vaccines indicates major underinvestment in an emerging global health threat.Nature biotechnology · 2025Article
- Bridging the gap in Chagas disease management: a mixed-methods study using an implementation science approach within the Brazilian primary health care system-'Implementa-Chagas/SaMi-Trop project'.Lancet regional health. Americas · 2025Article
- TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Chagas Disease Control-Many Approaches to Prospect.Tropical medicine and infectious disease · 2023Article
- Roles of ADP-Ribosylation during Infection Establishment byPathogens (Basel, Switzerland) · 2023Review
- Host cell cAMP-Epac-Rap1b pathway inhibition by hawthorn extract as a potential target againstFrontiers in microbiology · 2023Article
- Genomic surveillance: a potential shortcut for effective Chagas disease management.Memorias do Instituto Oswaldo Cruz · 2023Article
- Myocardial Injury in Patients With Acute and Subacute Chagas Disease in the Brazilian Amazon Using Cardiovascular Magnetic Resonance.Journal of the American Heart Association · 2022Article
- Air Pollution's Impact on Cardiac Remodeling in an Experimental Model of Chagas Cardiomyopathy.Frontiers in cellular and infection microbiology · 2022Article
- Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.Memorias do Instituto Oswaldo Cruz · 2022Article
- New Contributions to the Elimination of Chagas Disease as a Public Health Problem: Towards the Sustainable Development Goals by 2030.Tropical medicine and infectious disease · 2021Article
- Do the new triatomine species pose new challenges or strategies for monitoring Chagas disease? An overview from 1979-2021.Memorias do Instituto Oswaldo Cruz · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease was discovered in 1909 by the Brazilian scientist Carlos Chagas. After more than 110 years, many outcomes have been achieved in all research fields; however, Chagas disease remains a serious public health problem, mainly in Latin America, being one of the most neglected tropical diseases in the world. As a neglected disease, it receives very little financial support. Nevertheless, how much is actually spent? With this question in mind, the goal of the present work was to summarize all funding employed by multiple institutions in the Chagas disease field in a 10-year survey. From 2009 to 2018, Chagas disease received only USD 236.31 million, representing 0.67% of the total applied for all neglected diseases in this period. Mostly, the investments are concentrated in basic research (47%) and drug development (42.5%), with the public sector responsible for 74% of all funding, followed by the industry (19%) and philanthropy (7%). Relevantly, NIH (USA) alone accounted for more than half of the total investment. Taking into account that Chagas disease has a great socio-economic impact, it is clear that more investments are needed, especially from endemic countries. Furthermore, coordinated strategies to make better use of resources and incentives for the pharmaceutical industry must be adopted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.